Bank of America, Morgan Stanley, Nvidia and Dollar Tree rise premarket
NovoCure Ltd (NASDAQ:NVCR), currently valued at $1.37 billion, has seen its shares decline nearly 59% year-to-date. Chief Executive Officer Ashley Cordova has purchased 81,550 ordinary shares of the company on September 5, 2025. The shares were bought at a weighted average price of $12.2239, for a total transaction value of $996859. The prices for the purchases ranged from $12.02 to $12.47
Following the transaction, Cordova directly owns 437,569 ordinary shares of NovoCure.
In other recent news, Novocure announced the termination of its LUNAR-4 clinical trial for metastatic non-small cell lung cancer, citing the availability of real-world evidence. In Spain, the Ministry of Health has approved Novocure’s Tumor Treating Fields therapy for inclusion in the Spanish National Health System for adult patients with newly diagnosed glioblastoma, broadening access to this treatment. Additionally, Novocure has submitted a premarket approval application to the U.S. Food and Drug Administration for its Tumor Treating Fields therapy aimed at treating locally advanced pancreatic cancer, following the PANOVA-3 clinical trial results.
On the analyst front, Ladenburg Thalmann initiated coverage on Novocure with a Buy rating and a $30.00 price target, citing a positive outlook for the company’s Optune Gio treatment in glioblastoma multiforme. Meanwhile, H.C. Wainwright maintained its Buy rating and a $38.00 price target on Novocure after positive trial data for its pancreatic cancer treatment. These developments suggest a continuing interest in Novocure’s innovative cancer therapies and their potential impact on the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.